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Abstract 
Between the years 2014 and 2015, the world experienced a catastrophic outbreak of Ebola 
virus, which killed over 26,000 people. Several authorities and organizations actively participated 
in fighting the epidemic. Infectious disease modelers proved to be invaluable towards this goal. 
This report provides a background on the Ebola epidemic in West Africa and reviews the biological 
features of the Ebola virus. Moreover, this report applies a new model for Ebola propagation using 
data collected by the World Health Organization during the span of the outbreak. The model 
estimates the reproduction number and assesses the role of mitigation strategies in slowing down 
the progress of the disease. The report also concludes a review of recent advancements in vaccine 
production against Ebola. 
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Preface 
This report’s subject of interest is the Ebola Hemorrhagic Fever, the disease that killed 
thousands of people in West Africa since its outbreak in March 2014. I chose to investigate this 
topic while working with Dr. Scoglio’s networks group and finding out how important this 
research is for the two fields of biological engineering and computational epidemiology.  
In this report, I introduce various aspects of the Ebola Virus Disease such as its history, 
transmission mechanisms, and impact on West Africa. I then focus on two important topics related 
to the disease. The first being its epidemic modeling using extensive data from the World Health 
Organization. The second being vaccine development and therapeutic interventions. 
Finally, this report is based upon the work I did while I was supported as a research 
assistant by funds from the National Science Foundation under Grant No. SCH:1513639.   
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Chapter 1 - Introduction 
Ebola hemorrhagic fever (EHF), or simply Ebola, is a lethal disease caused by infection 
with Ebola virus. It is named based on the location of the first discovery of the disease in 1976 in 
Sudan and Zaire (now, the Democratic Republic of the Congo) near the Ebola River [1]. Since 
then, Ebola outbreaks have appeared intermittently in several African countries. Its symptoms start 
with headaches, fever and muscle pain during the first few weeks followed by vomiting, diarrhea 
and extensive internal and external bleeding. The main identified strains of the Ebola virus are 
Zaire, Sudan, Bundibugyo and Tai Forest [1].  
In this chapter, we review a brief history of Ebola including the spatial and temporal 
progression of the recent outbreak, mitigation strategies to prevent transmission, and the impact of 
the epidemic on West Africa. 
 
1.1. Brief History of Ebola 
Ebola first started in Sudan and Zaire in 1976 near the Ebola River, which infected over 
284 people with a fatality rate of 53%. Within a few months, the second Ebola virus, EBOZ, 
emerged from Yambuku, Zaire, where it infected 318 people with the very high mortality rate of 
88%. The third strain of Ebola, known as Ebola Reston (EBOR), was first introduced into US in 
1989 by infected monkeys imported from Mindanao, Philippines. Fortunately, only a few people 
were infected with EBOR, and those individuals did not develop Ebola hemorrhagic fever (EHF). 
The last strain of Ebola, Ebola Cote d'Ivoire (EBO-CI) was discovered in 1994 in Tai Forest, when 
an ethnologist unintentionally infected herself while doing a surgery on a dead chimpanzee [1]. 
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Ebola outbreaks have been intermittently experienced through history. However, all but 
the last outbreak, i.e., 2014 West Africa outbreak, were limited to a few cases. Figure 1 shows all 
the recorded Ebola outbreaks in the history. Prior to the 2014 Ebola outbreak, the maximum 
numbers of cases and deaths were 425 (2000-2001 Uganda outbreak) and 280 (1976 Zaire 
outbreak), respectively. As shown in Figure 1, the number of cases and deaths during the 2014 
Ebola outbreak made an unprecedented jump to 27,000 and 11,000 on July 18, 2015, respectively. 
Comparing previous experiences of Ebola outbreaks with the 2014 outbreak highlights that 
sporadic, small-scale occurrences of an infectious disease should not be taken as a guarantee of its 
little potential threat. 
 
Figure 1 Ebola outbreaks in history. Source: Centers for Disease Control and Prevention: 
http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html. 
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The 2014 West African Ebola epidemic has been the largest and deadliest Ebola outbreak 
in history (Figure 1). The outbreak started in December 2013 and severely affected countries 
including Sierra Leone, Guinea, and Liberia. Moreover, cases were also reported in Nigeria, 
Senegal, Mali, United States, United Kingdom, and Spain. Some features made this outbreak 
different and more intense than the previous ones. For example, Ebola spread into unprepared 
countries in West Africa, which did not have previous experience with Ebola outbreak and required 
mitigation measures to control it. Furthermore, instead of the virus being transmitted through 
isolated, rural areas like previous outbreaks in Central and East Africa, this time, it quickly moved 
to densely populated urban hot spots. Also, the low levels of literacy, poor access to health 
information, and delayed public health campaigning made the affected situation worse. These 
factors contributed to the deadliest Ebola outbreak in history. To better understand the extent of 
the outbreak spread and its impact on West African countries, we review the mechanisms through 
which Ebola virus can spread. 
1.2. Transmission Mechanisms of Ebola 
Ebola disease is a zoonotic disease, i.e., it involves animals and humans. In particular, 
researchers consider fruit bats as the primary host for the Ebola virus. Figure 2 depicts a schematic 
of the main transmission mechanisms of the Ebola virus.  The transmission of Ebola virus among 
fruit bats is enzootic, i.e., the virus routinely transmits among them, making fruit bats the primary 
reservoir for the virus. In the event of a spillover of the virus from the primary reservoir to 
secondary hosts, Ebola virus can be transmitted among other animals and humans as in epizootic 
cycle. Initially, Ebola virus entered the human population through direct contacts with infected 
animals like chimpanzees, gorillas, fruit bats, monkeys, forest antelope, and porcupines found in 
the rainforest [1]. After animal-to-human transmission, Ebola virus then spread in the human 
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population through direct contact with the blood or other bodily fluids of infected people. There 
has been no indication that mosquitos or other insects can be vectors for Ebola virus transmission. 
Only mammals such as bats, monkeys, apes, and humans can spread the virus and become infected 
with Ebola virus.  
  
Figure 2 Major transmission mechanisms of Ebola. Source: Centers for Disease Control and 
Prevention: http://www.cdc.gov/vhf/ebola/resources/virus-ecology.html  
 
The infection transmission mechanism from an infected animal or person to a healthy one 
is mainly through direct contact with blood or other bodily fluids of an infected individual. EHF 
can develop upon direct contact with blood, secretions, organs, or other bodily fluids of an infected 
human or person. Bodily fluids include vomit, urine, semen, vaginal fluids, saliva, sweat, tears, 
mucus, and feces. When blood or bodily fluids of an alive or deceased infected person touch 
another person’s mouth, nose, eyes, wound, or open cut, the contact is considered direct. Ebola, in 
some rare cases, can be transmitted through sex with an infected or even a recovered male person. 
In summary, Ebola can be transmitted to humans in two ways. First, the virus can move from one 
animal to another animal in the wildlife, and then from an infected wild animal to a human. Second, 
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the virus can be transmitted from an infected human to another human. The latter happened in 
West Africa during the 2014-2015 Ebola outbreak, the deadliest and the largest outbreak of Ebola 
experienced so far. 
 
1.3. Ebola Spatial and Temporal Propagation in West Africa 
Ebola disease spread in 2014 became a severe global concern when it affected cities in 
West Africa with major commercial airports such as Conakry, Freetown, Monrovia, and Lagos. 
Figure 3 shows the spatial distribution of new and total cases in Guinea, Liberia, and Sierra 
Leone until March 27, 2016.  
 
Figure 3 Spatial distribution of Ebola cases in West Africa. Source: World Health Organization 
(WHO). http://www.who.int/csr/disease/ebola/maps/en/  
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As Figure 3 indicates, those regions in Guinea and Libera that are closer to Sierra Leone 
are more severely affected compared to areas far from Sierra Leone. According to the latest 
report of CDC [1], as of April 13, 2016, the maximum number of cases and deaths are 14,124 
(Sierra Leone) and 4,810 (Liberia), respectively. The spread of Ebola from West Africa to other 
countries occurred primarily due to international travels of exposed individuals. Even though the 
total number of external infections was very low, fear of globalization of the epidemics urged 
governments to impose increased monitoring and restrictions to international flights originating 
from affected West African countries. 
 
1.4. Mitigation Strategies to Stop and Contain the Ebola Outbreak 
Since there is no proven vaccine for Ebola on the market yet, mitigation strategies play a 
significant role in preventing transmission of the virus. The risk of transmission is particularly high 
in health care settings. Therefore, health care workers should be mindful of preventive practices 
such as wearing the protective clothing (e.g., masks, gloves, goggles, and gowns) and use 
infection-control measures (e.g., complete equipment sterilization and routine use of germicide). 
In addition, they should isolate patients from exposed people without full protection. All these 
techniques are used to avoid any contact with the blood or fluids of an infected patient. Moreover, 
direct contact with the body of a dead patient should be prohibited, because the virus can also 
spread through contact with a dead person’s body fluid. 
During the 2014-2015 outbreak, governments of infected nations have taken extraordinary 
measures under the supervision of the World Health Organization (WHO), and in close 
collaboration of international public health experts and workers. In Liberia, the government 
7 
ordered all schools to remain closed temporarily. Ministry of Health allocated resources for 
disinfection of the affected areas with chemical disinfectants while health worker would check on 
people from house to house to observe whether they were infected or not, and isolate the infected 
people to treatment facilities. The Ministry of Health complemented these efforts by conducting 
public education and awareness on the dangers of Ebola and the necessary measures to avoid 
contracting and spreading the virus. Places like churches and mosques, shopping centers, and other 
public areas were required to provide hand washing facilities and to post notices about the Ebola 
epidemic for more awareness [1]. 
Similar to many other outbreaks of infectious diseases among humans, travelers are the 
most concerning vectors [1]. Travels between cities and countries can allow the virus to spread 
and as consequence worsen the epidemic outbreak. Therefore, one of the first strategies to stop 
further propagation of Ebola is to quarantine infected people or affected areas. In the case of the 
2014-2015 Ebola outbreak, quarantining was practiced as well. For example, the residents of Port 
Loko, Bombali, and Moyamba, which were the hotspots for Ebola’s propagation, were quarantined 
with the orders of the Sierra Leonean president, Ernest Bai Koroma. The total population of the 
quarantined area was about a million people, almost a third of the country’s population. Also, 
People traveling to the quarantined areas or moving to the isolated areas were carefully monitored 
to ensure that the deadly Ebola disease did not transmit outside of the region. 
The CDC issued travelers’ alert to all US residents, asking them to avoid travel to Guinea, 
Liberia, and Sierra Leone. Those traveling to these regions were asked to avoid any contact with 
the blood and body fluids of people with Ebola. Furthermore, enhanced monitoring was placed on 
international flights originating from one of the affected countries, and in particular, if the US was 
the final destination. 
8 
1.5. Effects of Ebola on West Africa 
Even though mitigation strategies were helpful to slow down outbreak spreading, the Ebola 
outbreak already imposed severe economic difficulties and food shortage on West African 
countries. According to the UN Food and Agriculture Organization (FAO) [4], the three affected 
countries, Guinea, Sierra Leone, and Liberia were at the risk of facing a terrible food shortage due 
to restrictions on movements and the fear of Ebola spread. The fear of getting infected kept many 
people away from markets, farms, schools, and other places. Furthermore, since eating bushmeat 
was banned, hunters had to stay in their homes, and due to restrictions on travels, many farmers 
were not able to go their fields and farms to harvest the rice and corn. Moreover, limitations in 
trade relations through the seaports lead to the high prices of cereal, corn, palm oil, meat, and 
cocoa. The rapid increase in the food prices caused serious issues for many people of affected 
countries. In response to this crisis, the UN FAO and the World Food Program sent 65,000 tons of 
food to feed about 1.3 million people in West Africa. 
 
1.6. Conclusion  
In this chapter, after a brief history of Ebola and its transmission mechanisms, we reported 
the 2014 outbreak and its impact on West Africa. Then, we discussed some mitigation strategies. 
When such outbreak happens, it is very crucial to act immediately and effectively to fight further 
spread and reduce the toll on people and global safety. For designing successful mitigation 
policies, particularly under resource limitations, quantitative understanding of the disease outbreak 
and its time projection is invaluable. Computer models of disease spread played a significant role 
to this end during the 2014 Ebola outbreak. The following chapter is devoted to modeling Ebola 
propagation.   
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Chapter 2 - Modeling Ebola Propagation 
Computational epidemic modelers played a valuable role to help health authorities allocate 
resources to mitigate effectively and efficiently Ebola from spreading. The objective of a 
computational model is to provide mathematical and simulative tools to describe, understand, and 
predict the spatial and temporal projection of an outbreak, as well as to evaluate mitigation 
strategies for informed decisions. An epidemic model uses biological features of the disease as 
well as recorded incident cases to set up a computational tool. Several modeling approaches have 
been proposed for the Ebola outbreak [4–11].  In this chapter, we review a background on modeling 
Ebola spread, propose a simple epidemic model inspired by a recently proposed model [4], state 
our data collection effort from WHO reports, and finally apply our model to real incidence data in 
Liberia. We conclude the chapter by discussing our results. 
 
2.1. Background on Epidemic Modeling 
Epidemic models are mathematical descriptors of the dynamics of communicable diseases 
among a group of individuals in society. Upon introduction of infection in a population, several 
questions become immediately relevant. For example, will the infection be limited to a few cases 
and die out shortly after introduction? Does it have the potential to become an epidemic? What are 
possible conditions that can lead to such catastrophic event? What would be the total cost of the 
outbreaks, say, measured in terms of the total number of individuals who experience the infection?  
What is the growth rate? When can we expect the maximum peak of the epidemic, after which 
infections tend to slow down? What are the best mitigation strategies to suppress the epidemics? 
How should a health authority prioritize strategies, allocate resources to most effectively, and 
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efficiently eradicate the disease? The objective of epidemic modeling is to help answering the 
above questions. 
Efforts to capture dynamics of communicable diseases date back to pioneering work of 
Daniel Bernoulli, who used simple differential equations to model the spread of smallpox [12]. 
However, there has been a substantial amount of work devoted to epidemic modeling during the 
past decade, particularly due to recent large-scale outbreaks as well as due to advances in 
computational power. 
There are several approaches to epidemic modeling. For example, models can be 
deterministic or stochastic. The modeling scale can be compartmental — where the whole 
population is divided into groups depending on their infectious state, meta-population — where 
geographically distant subpopulations are considered, or individual-level — where disease 
propagation is studied from on individual to another. From a computational complexity 
perspective, deterministic compartmental models are the simplest while individual-based models 
are the most complex. 
In this report, we only consider deterministic compartmental models. In such models, a 
population of interest is divided into different compartments [13]. A typical model considers, at 
least, a susceptible compartment and an infected compartment. The infected compartment denotes 
the subset of the population who have received the infection and can potentially infect others. The 
susceptible compartment denotes those individuals who have not contracted the infections but are 
at risk of contracting it if they are exposed to an infected individual. Depending on the disease, 
modelers add more compartments to comply with reality. For example, for a disease such as 
chicken pox, an infected individual becomes immune to future infections after the infectious 
period. For such cases, a third “removed” compartment is usually considered. People belonging to 
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the removed compartment are those who had previously contracted the disease and now are 
immune; in other words, they are removed from future dynamics of infection growth. We should 
point out that not all infections lead to immunity. For example, an infected individual with a 
sexually transmitted disease can potentially get the infection repeatedly. Another very common 
compartment in epidemic models is the exposed compartment. Exposed are those individuals who 
have received the infection but are still in the incubation period and cannot pass the virus to another 
susceptible person. For example, models of Ebola disease commonly include the exposed 
compartment since an individual typically needs 5-21 days after exposure to the Ebola virus to 
show symptoms and become infectious [1]. 
One of the key descriptors of an infectious disease spreading is the basic reproduction 
number, denoted by R0. This quantity measures how aggressively a virus spreads within a 
population [13]. The epidemiological definition of R0 is the expected average number of secondary 
infections from a single initial infected individual in an entirely susceptible population during its 
infectious period. Importantly, R0 provides a criterion for the epidemic outbreak. If R0<1, then 
initial infections will disappear soon. The reason is that from a single infected individual, the 
average secondary infected cases are less than one. Therefore, within a short period, all infected 
individuals are recovered. Contrarily, when R0>1, then initial infections have the chance to grow 
exponentially in the population. The awareness is that if for example R0=2, the single initial 
infected individual leads to 2 new cases, who in turn, leads to 4, 8, 16 new cases and so on [13]. 
The epidemiological definition of R0 is not very practical when dealing with realistic 
incidence data because it is not directly measurable. A standard approach is that parameters of an 
epidemic model are tuned so that model outputs fits observed incidence data. Therefore, since such 
models are mathematical equations, a theoretical expression for the value of R0 can be computed. 
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2.2. An SEIR Model For Ebola 
The SEIR model proposed in [4] has the following structure: The population is divided into 
five compartments, namely, susceptible (S), exposed (E), infected (I), recovered (R), or dead (D). 
Figure 4 illustrates the transition among these compartments. 
 
 
 
 
 
 
 
 
 
 
As Figure 4 indicates, in SEIR model susceptible individuals (S) become exposed at rate 
βI, exposed individuals (E) become infected at rate σ, infected individuals (I) recover or die at rate 
γ. The mortality rate is f, which is a number between 0 and 1. For example, f=0.4 means 40% of 
infected individuals will die. In this model, it is assumed that a mitigation effort is going on which 
is reducing the infection rate 𝛽 at a reduction rate k. 
According to these transition rules, we can derive the differential equations governing the 
evolution of fraction of each compartment (see [4]). 
𝑑𝑆𝑑𝑡 = −𝛽𝑆𝐼	  𝑑𝐸𝑑𝑡 = 𝛽𝑆𝐼 − 𝜎𝐸	  𝑑𝐼𝑑𝑡 = 𝜎𝐸 − 𝛾𝐼	  
S 
D 
R 
I E βI σ 
(1-f) γ 
f γ 
Figure 4 Transition diagram for SEIR Ebola model proposed in [4]. 
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𝑑𝑅𝑑𝑡 = 1 − 𝑓 𝛾𝐼	  𝑑𝐷𝑑𝑡 = 𝑓𝛾𝐼 𝑑𝛽𝑑𝑡 = −𝑘𝛽 
(Eq.1) 
 
In the above set of differential equations 𝑆 + 𝐸 + 𝐼 + 𝑅 + 𝐷 = 1, the initial condition is 𝑆, 𝐸, 𝐼, 𝑅, 𝐷 |456 = (1 − 89 , 0, 89 , 0,0)  and 𝛽|456 = 𝑅6𝛾, assuming that at the initial time there is 
only one infected individual in the population and the rest are susceptible, while the basic 
reproductive number is 𝑅6 to be estimated from data. Stability analysis of Eq.1 reveals that for 
SEIR model 𝑅6 = 𝛽/𝛾. 
The MATLAB code for the SEIR model in Eq. 1. is as follows: 
% Population 
N=1000000; I0=1; 
 
% SEIR model paramters 
gamma =1/5.61; sigma=1/5.3; f=0.71; R0=1.59; beta = gamma*R0; k=0; 
SEIRfun=@(t,x) SEIR(x,k,gamma,sigma,f); 
 
T=8*30;   % Simulation Time 
[t,x] = ode45(SEIRfun, [0:T], [1-I0/N 0 I0/N 0 beta]); 
 
% Computing Populations 
S=x(:,1)*N; E=x(:,2)*N; I=x(:,3)*N; R=x(:,4)*N; D=N-S-E-I-R; 
 
% Plotting 
figure(1); 
plot(t,I+D+R,'r', 'LineWidth', 3) 
hold on; 
plot(t,D,'k', 'LineWidth', 3) 
 
legend({'Cases', 'Dead'}) 
ylim([0,10000]); 
xlabel('Time (day)','fontsize',14); 
ylabel('Population','fontsize',14); 
ttl=['Liberia R0=',num2str(R0)]; 
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title(ttl,'fontsize',14); 
 
% Script for function SEIR 
 
function dx = SEIR(x,k,gamma,sigma,f) 
dx = [0; 0; 0; 0; 0]; 
 
beta=x(5); 
 
dx(1) =-beta* x(1) * x(3); 
dx(2) = beta * x(1) * x(3)-sigma*x(2); 
dx(3) =sigma*x(2)-gamma*x(3); 
dx(4) =(1-f)*gamma*x(3); 
dx(5)=-k*x(5); 
 
end 
 
2.3. Exploratory Simulations of the SEIR Model 
The SEIR model of Ebola explained in the previous section can show the evolution of the 
size of each subpopulation through time. The model has several parameters that need to be 
estimated either from prior knowledge about the virology of the disease or should be estimated 
from data. Before using any parameter estimation, we first simulate the model with synthetic 
values for 𝑅6 to have a primary understanding of the model. Here, we have chosen a population of 
N=1,000,000 individuals with I0=10 initial infected cases. According to recorded clinical data, we 
choose the time to recover or die as 5.3 days  (γ=1/5.3), and the time that an exposed individual 
becomes infected as 5.61 days  (σ=1/5.61). Furthermore, we assume a 40% morbidity rate (f=0.4). 
Our numerical exploration of the model, as depicted in Figure 5, shows that R0 has a 
significant role in the number of infected: the higher the R0 value, the greater the number of infected 
cases. For example, in Figure 5a for R0=1.56, the number of dead cases is about 22,000, whereas 
the death counts jump to 35,000 for R0=2.53 in Fig. 5c. Furthermore, we see that 
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size occurs earlier for larger infection rates. For example, in Figure 5a when R0=1.56, the peak of 
epidemics happens around day 175, while for R0=2.53 in Figure 5c, the peak of epidemics around 
day 85. A long time to the peak of infection allows more time for mitigation efforts and hence 
makes eradication of the disease more feasible. 
  
 
Figure 5 Simulation results for three scenarios with different reproduction numbers: (a) 
R0=1.56, (b) R0=1.80, and (c) R0=2.53, shows its impact on the projected number of exposed, 
infected, recovered, and dead cases. 
 
 
(b) (a) 
(c) 
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2.4. Real-time Data Collection of Ebola Cases 
We have regularly collected data from Health Map [2] which is an accessible, automated 
electronic information system for monitoring and visualizing reports of global disease outbreaks. 
Health Map provides a comprehensive view of the current global infectious diseases according to 
geography, time, and infectious disease agent. In March 2014, the Healthmap software tracked 
reports of Ebola in West Africa, and they were updating daily data about Ebola outbreak cases and 
death. The HealthMap team created a dedicated HealthMap visualization [3]. We have collected 
all the reported data from HealthMap in an Excel file. Figures 6-8 show the number of total cases 
and the number of death cases in Guinea, Liberia, and Siera Leone, respectively. A total number 
of cases at a given date includes all the cases that have experienced the infection and has been 
detected by that date. Death numbers at a specified time show the total number of individuals who 
have died as the result of Ebola disease. 
 
   
Figure 6 Ebola cases and death numbers in Guinea. Data collected from [2]. 
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Figure 7 Ebola cases and death numbers in Liberia. Data collected from [2]. 
  
 
  
Figure 8 Ebola cases and death numbers in Sierra Leone. Data collected from [2]. 
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2.5. SEIR Model Fitting to Actual Ebola Data 
The SEIR model (Eq. 1) for Ebola can be applied to real data of Ebola cases and death 
numbers collected in Section 2.4. For this end, we need to estimate the parameters involved in the 
model, namely σ, γ, R0, k, f. Following steps explain our approach in this report for parameter 
estimation: 
1.   Choose σ=1/5.61 day-1 and γ=1/5.3 day-1, which are obtained according to clinical record 
of the Ebola virus. 
2.   Change the reproductive number R0 and the infection reduction rate k so that the output of 
the SEIR model in Eq.1. obtained using the MATLAB codes in section 2.2 fit the number 
of Ebola cases collected in section 2.4. This step is trial-and-error, i.e., values of the two 
parameters R0 and k are tweaked until a reasonable fit is obtained. More advanced 
parameter estimation methods could improve the model fitting, which is out of the scope 
of the current report. 
3.   Select f such that death numbers fit the reported values. This step is a simple linear 
regression on the total number of cases as the x-axis and the total number of deaths as the 
y-axis. 
4.   Change the values of the basic reproduction number (R0) and mitigation rate k, so that 
predicted values fit well to the actual recorded data. 
5.   As a goodness of fit measure, plot the predicted against actual values. 
Figures 9, 10, and 11 show the model fitting to the actual data in Liberia, Guinea, and Sierra Leone, 
respectively. The best parameters that we found were R0=1.85 and k=0.0027 (1/day) for Liberia, 
R0=1.52 and k=0.0023 (1/day) for Guinea, and R0=1.8 and k=0.0028 (1/day) for Sierra Leone. 
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Figure 9 Model fitting to the real Ebola data in Liberia.  The small circles show the actual recorded 
data, and the lines are the prediction of the epidemic model [2]. 
 
 
Figure 10 Model fitting to the real Ebola data in Guinea.  The small circles show the actual 
recorded data, and the lines are the prediction of the epidemic model [2]. 
0 20 40 60 80 100 120 140 160 180 200
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
Time (day)
Po
pu
lat
ion
Liberia R0=1.85
 
 
Cases
Dead
20 
 
 
Figure 11 Model fitting to the real Ebola data in Sierra Leone.  The small circles show the actual 
recorded data, and the lines are the prediction of the epidemic model [2]. 
 
As can be seen in Figures 9-11, there is a good agreement between the model output and 
actual recorded numbers, despite our rudimentary approach to parameter estimation.  To further 
illustrate the goodness of fit in an example, we have plotted the predicted values for the number 
of cases against actual numbers for the case of Sierra Leone in Figure 12. The slope of the linear 
fit is very close to 1 with, R2=0.99, indicating that actual and predicted values are reasonably close. 
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Figure 12 Predicted vs. the actual number of Ebola cases in Sierra Leone. Actual data from [2] 
 
2.6. Conclusion  
We computed the basic reproductive number according to a SEIR model for Ebola in Eq. 
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we did not include the complete data up to the end of 2015 is that R0 is a quantity related to the 
early growth of the epidemic. Since, as recorded data indicates, the epidemic started to slow down 
in 2015, incorporating the full data would bias the estimation towards lower values.  The computed 
value for R0 for Liberia (1.85), Guinea (1.52), and Sierra Leone (1.8) in our simulation is 
compatible with other estimations. For example, Althaus [4] found R0=1.59 (Liberia), R0=1.51 
(Guinea), and R0=2.53 (Sierra Leone), which is comparable to our results except in the case of 
Sierra Leone, which we believe is due to their very large mitigation rate in their calculations. 
The values R0 (in the range of 1.52–1.85) for the basic reproductive number indicates that 
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infectious diseases such as measles 12–18, smallpox 5–7, SARS 2–5, and influenza 2–3, value 
R0=1.85 places Ebola among slow viruses. 
The analysis in this sections found an estimation for the mitigation rate for Liberia as 
k=0.0027 (1/day), which means mitigation efforts were indeed slowing down the infection. 
According to the last equation of Eq.1 for β, this value means it would take about 𝑇 =
?@ ABC ~227	  𝑑𝑎𝑦𝑠~7.6	  𝑚𝑜𝑛𝑡ℎ𝑠	  to bring the reproduction number below 1, which in this case 
would correspond to late 2014. 
Obviously, the real scenario of Ebola propagation is very complex that are not considered 
in the SEIR model. Yet, the simple deterministic SEIR model provides some insights into the 
dynamics of the disease which might not be intuitive.   
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Chapter 3 - Vaccines and Therapeutics Development for Ebola 
This chapter provides a background on vaccine development against Ebola virus, reviews 
some of the primary vaccine and therapeutic products, and discusses possible plant-based 
production procedures. 
3.1. Brief history of Ebola vaccines and therapeutics 
Vaccines and therapeutics are crucial in the management of infectious disease. Vaccines 
are intended to immunize susceptible people against possible, future infections while therapeutics 
refer to medical treatments given to an infected individual to help them recover from the disease 
or at least alleviate the symptoms. Unfortunately, during the recent Ebola outbreak, there were no 
vaccines against Ebola for humans. Even if a clinical trial proved to be effective in humans, 
producing large quantities of vaccines would not be feasible for months and years. Moreover, the 
virology of Ebola virus has not been described enough due to difficulties in getting samples and 
laboratory studies and analysis, and high biohazard containment requirements. Plus, previous 
outbreaks were primarily in remote areas which were not populated. 
Since the first detection of Ebola in 1978, researchers have been trying to develop vaccines 
against this virus. A significant amount of this effort has focused on vesicular stomatitis virus 
(VSV) expressing the Ebola virus glycoprotein (VSV-EBOV), which showed good efficacy in 
protecting rodents and nonhuman primates against Ebola virus. Unfortunately, VSV-EBOV did 
not progress to clinical trials in humans mainly because, before 2014, the appearance of Ebola was 
rare and could not justify support from private pharmaceutical companies. Figure 13 depicts the 
historical timeline of vaccine development against Ebola virus. As can be seen in Figure 13, long 
before the 2014 Ebola outbreak, Ebola vaccines were developed and successfully tested in rodents 
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and non-human primates (DNA 2000 and VSV 2005). Although, human vaccines were never 
developed and tested until 2015, after the outbreak.  Perhaps thousands of lives could have been 
saved during the 2014 West Africa outbreak if the potential threat of Ebola had never been 
overlooked and research for the development of a human vaccine against Ebola had continued. 
 
 
Figure 13 Ebola virus vaccines development timeline [14]. 
 
In addition to vaccines, drug development also began in 2002. The efforts were supported 
by governmental institutes such as National Institute of Health (NIH), United States and Public 
Health Agency of Canada. In 2004, an antibody therapeutics named ZMapp was developed by the 
Leaf Biopharmaceutical Inc. (San Diego, CA, USA) [17]. 
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3.2. Ebola Diagnosis, Therapeutics, and Vaccines 
The first step to fight Ebola virus disease is finding a diagnostic way to detect it. Enzyme-
linked immunosorbent assay (ELISA) and real-time reverse transcription-polymerase chain 
reaction (rRT-PCR) are the common methods for Ebola virus diagnosis. ELISA is a standard 
method for detection of antigen or antibody. However, antibody-capture ELISA is not the best 
method to be applied for early stage diagnosis since it usually takes 1 or 2 weeks for antibodies to 
become evident. Virus isolation is also limited to laboratories with a biosafety level 4. After virus 
isolation, rRt-PCR is the most useful diagnostic method to recognize the presence of Ebola virus 
in specific genes. The next step after diagnosing EDV is treating the infected patient by an 
advanced form of therapeutics and providing susceptible people at risk with proper vaccination. 
Unfortunately, bio-processing of medications is very slow as any research associated with EVD is 
very risky and requires specific facilities comparable to biosafety level 4 laboratories.  
Several vaccines and therapeutics have been proposed for Ebola. The most common 
therapeutics are ZMapp, Favipiravir, and TKM-Ebola and the most common vaccines are VSV-
EBOV, cAd3-EBO Z. Table 1 shows a list of anti-Ebola therapeutics and vaccines, along with 
their manufacturer, production format, and their latest clinical trial phase. Unfortunately, most of 
the vaccines and therapeutics have only been tested in small rodents, pigs, or nonhuman primates. 
Unfortunately, only until several months after the outbreak, no phase II clinical and field trials was 
ever carried out on any of the vaccines and therapeutics.  
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Table 1 Drug and vaccine candidates for clinical trials. Adapted from [17]. 
Candidate  Manufacturer Format Clinical 
trial 
Drugs ZMapp Mapp Biopharmaceutical, 
USA 
Plant-derived 
antibody cocktail 
Not yet 
TKM-
Ebola 
Tekmira, Canada RNAi Phase I 
Favipiravir Toyama Pharmaceutical 
Co., Japan 
RNA polymerase 
inhibitor 
Phase I 
Vaccines cAd3 GSK, UK (developed by 
NIH, USA) 
Chimpanzee 
adenovirus-based 
DNA vaccine 
Phase I 
VSVΔG-
ZEBOV 
NewLink Genetics Co., 
Canada (developed by 
Public Health Agency of 
Canada) 
Recombinant 
vesicular stomatitis 
virus-based VLP 
vaccine 
Phase I 
 
 
3.2.1. Therapeutics Development 
The most common therapeutics for Ebola virus disease treatment are ZMapp, Favipiravir, 
and TKM-Ebola. ZMapp is a mixture, or cocktail, of three monoclonal antibodies (mAbs) against 
Ebola virus. These antibodies target the glycoprotein of the Ebola virus, preventing virus 
replications and neutralizing them. Antibody therapeutic ZMapp—which was under development 
from 2004 by Leaf Biopharmacutical Inc.—had proven helpful to protect chimpanzees from Ebola 
virus earlier, however, it was still under study before the West Africa outbreak. In April 2014, 
ZMapp was tested on two American medical staffs who had contracted the Ebola virus in Liberia, 
and for the first time, ZMapp showed therapeutic effectiveness against Ebola in humans. [21]. 
Even though ZMapp seems to have effective ingredients to save EVD patients, it still has some 
limitation to become the common Ebola therapeutics in clinical fields [17]. 
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The intriguing aspect of ZMapp is its possibility of plant-based production. Production of 
proteins or antibodies from transgenic plants, genetically modified plants that can express a 
particular protein of interest, is very time consuming and not very suitable for responding to sudden 
threats like the Ebola outbreak. Alternatively, Mapp was able to produce the Ebola antibodies on 
tobacco (specifically, Nicotiana benthamiana) leaves as transient expression. The plant has been 
able to produce pharmaceutical proteins under highly controlled conditions. The main advantage 
of this plant-made antibody is being a quick process and being scalable to mass production [21]. 
ZMapp production can be explained in the following simple steps [17]:  
1.   Tobacco is planted under controlled conditions for six weeks. The tobacco leaves will 
serve as the transient expression platform. 
2.   Mice are incubated with a recombinant vesicular stomatitis virus, where its 
glycoprotein (GP) has been replaced by GP of the Ebola virus. In this way, the 
immunological response of the mouse would reveal the important neutralizing 
antibodies against the Ebola virus. 
3.   These antibodies are cloned for human IgG and coded on bacterial carriers to be 
transferred to tobacco leaves. 
4.   The bacterial carriers are then transformed to six-week-old tobacco leaves using 
methods of agroinfiltration, enabling the tobacco plants to express human anti-Ebola 
mAbs. After this step, it typically takes about four days for the tobacco leaves to express 
the desired amount of mAbs. 
5.   Finally, antibodies are purified after harvest. A typical expression yield for ZMapp is 
50 µg of IgG per 1 gram of leaves. 
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The use of tobacco to produce ZMapp attracted an unprecedented global attention 
regarding potential of plant-based pharmaceutics (PMPs) in saving lives. Mapp substantiated that 
plants are a promising medium for the rapid production of antibodies to face bioterrorism or 
possible natural infection disease outbreaks [18]. Not only plants are very efficient in producing 
complex protein, they can be easily planted and sclaed up. In addition, plant-based pharmaceuticals 
require significantly lower facility and production costs compared to traditional cell culture 
methods. EVD outbreak in West Africa has highlighted an excellent opportunity for the use of 
plant-based pharmaceutical [20] as well as their limitations. 
In addition to ZMapp, Favipiravir and TKM-Ebola are other successful therapeutics against 
Ebola [17]. Favipiravir is an RNA polymerase inhibitor that can be synthesized  by chemical 
reactions. This drug is an effective treatment for both influenza and Ebola hemorrhagic fever 
(EHF) since these two diseases have a similar mechanism. RNA polymerase plays a critical role 
in the replication of Ebola virus similar to influenza. Favipiravir is under the clinical phase 3 as an 
influenza treatment. Studies show this antiviral is successful in curing  patients with early phase 
of EVD. Another EVD theraputic drug is TKM-Ebola which include a combination of three small 
interfering RNAs. TKM-Ebola prevents the reproduction of Ebola Virus by blocking three out of 
seven effective proteins in Zaire Ebola virus, namely, L polymerase, membrane-associated protein 
(VP24), and polymerase complex protein (VP35). It was successful in animal tests and also was 
applied in phase 2 clinical trials. Due to the ability to produce a large amount of RNAi within a 
short period, TKM-Ebola is one of the important therapeutic treatment in West Africa outbreak 
[17].  
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  3.2.2. Vaccine Development 
Researchers have been studying vaccine candidates since Ebola was identified in 1976. 
Since then, vaccine candidates have only been tested on animals in preclinical stages and 
acceptable results have not been achieved for nonhuman primates. Some challenges can be linked 
to obligations for high level safety facilities as well as lack of enough financial incentive for 
continued research. Studies on the use of an EVD prevention started during early 2000s, but only 
recently have achieved promising results in animals like guinea pigs and chimpanzees. For 
production of DNA vaccinces for Ebola, nucleoprotein or glycoprotein (GP) of Ebola virus is 
cloned into a plasmid backbone containing the host T-cells. The process for producing the DNA 
plasmid involved bacterial cell cultures from Escherichia coli resulting in intramuscular injectable 
liquid after fermentation and purification [22]. It  makes cells to produce anibody against inserted 
antigen-delivering DNA and it leads to a response of host immune system by increasing the 
immunization and preventing replication of EVD virus. Injecting the plasmid cloned by GP into 
animals resulted in stable production of anti-Ebola antigens. Still, the ability of humans immune 
system was less efficient in comparison to rodents. In order to boost antigen production in human, 
several research efforts looked for combining the plasmid with appropriate viral vectors [17]. 
  Recombinant vesicular stomatitis virus Ebola vaccine (rVSV-EBOV) 
Recombinant vesicular stomatitis virus known as rVSV-EBOV is a bivalent vaccine 
against Ebola virus, designed by National Microbiology Laboratory in Canda and the Public 
Health Agency of Canada and New Link Genetics. It contains a genetically engineered vesicular 
stomatitis virus (VSV), which can express the Ebola glycoprotein (GP). Viral particles replicate 
like VSV but express the ZEBOV glycoprotein which is responsible for receptor binding between 
ZEBOV and host target cell [19]. Various methods of rVSV-EBOV vaccine delivery like oral, 
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intranasal, and intramuscular injections have shown a general immune reaction to this virus 
protecting animal models completely from the Ebola virus 
Vesicular stomatitis virus is considered to be appropriate choice as a recombinant DNA 
vaccine platform. The advantage of such DNA vaccine is that it can protect hosts against not only 
Ebola but also many other filoviruses. VSV virus is an animal pathogen which does not show any 
harmful symptoms in human [19]. As a result, preclinical testing shows rVSV-ZEBOV is not only 
safe for medical use in the human population, but it also provokes a rapid and durable response in 
the human immune system. Moreover, rVSV vaccine can be a good candidate to support many 
filoviruses like ZEBOV, Sudan Ebola virus, and Marburg virus [19]. 
The most advanced form of rVSV Ebola vaccine, VSVΔG-ZEBOV vaccine, was recently 
developed by the Public Health Agency of Canada and NewLink Generics Corporation. The 
VSVΔG-ZEBOV vaccine contains diluted recombinant VSV concentration whose surface 
glycoprotein gene has been replaced with Ebola virus Zaire GP. This vaccine was highly effective 
in animals showing 100% protection on them. Moreover, it can also be rapidly cultured, and it is 
fast growing. 
 
  cAd3 Ebola Vaccine (cAd3-ZEBOV) 
Scientists at GlaxoSmithKline (GSK) and National Institute of Health (NIH) developed a 
vaccine from a chimpanzee adenovirus named Chimp Adenovirus type 3 (CAd3). This vaccine 
was designed to express glycoproteins (GP) which were taken from Ebola Virus. It expressed 
Ebola GP gene in hosts after vaccination and will produce an anti-cAd3 antibody which can cause 
an immune response against Ebola Virus Disease. Two types of  cAd3 Ebola vaccines are a 
monovalent vaccine, which protects animals from  Zaire strain and a bivalent vaccine which is 
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against both Zaire strain and Sudan strain [17]. Adenovirus vector has been studied as a successful 
platform for the DNA vaccine. Plus, it can be helpful for other infectious pathogens like HIV and 
tuberculosis. The main advantage of using Chimpanzee adenovirus vector is its safety since the 
animal vector cannot be replicated in human hosts. The cAd3 vaccine was tested in 16 animals and 
produced an excellent result defending animals from Ebola.  
 
 3.3. Further Discussion 
The vaccine and therapeutic development process is an ongoing process because genes in 
the virus are changing as the disease spreads. Changes may occur when the virus lives in animals 
between outbreaks in people. The other possibility is that the virus mutates when it moves through 
a human population. These changes are imperative because if theraputics or vaccines are 
developed to treat earlier forms of the virus, they might not work effectively on future ones. 
Additionally, patient’s immune system plays a significant role in recovery. It’s not proven that 
people who survive from Ebola will become immune for lifetime. They might still get the different 
kind of Ebola virus. Some of the therapeutics and vaccines have already been used on patients 
within the United States, and several which showed efficacy in animal tests, now are in the clinical 
trials in West Africa.  
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Chapter 4 - Conclusion 
In this report, we discussed introductory information about Ebola virus and its transmission 
methods, followed by reviewing the 2014 Ebola outbreak in West Africa, its severity and impact, 
and mitigation strategies to manage the outbreak. We discussed how infectious disease modelers 
help design these strategies. 
In Chapter 2, we provided a basic epidemic model for Ebola and applied it to real incidence 
data in Liberia. Through simple trial-and-error approach, we obtained a reproductive number of 
R0=1.85 for the Ebola outbreak in Liberia, which is consistent with reported values in the literature. 
Furthermore, we found that mitigation efforts, simply reflected in our model as infection reduction 
rate k—in the case of Liberia k=0.0027—was significant to contain the disease spreading, and 
potentially saving thousands of lives. Even though our model did not incorporate numerous factors 
affecting the propagation of the disease, it was able to provide a time projection of the virus 
propagation. This simple modeling effort signifies the importance of epidemic modeling for 
mitigation and policy making.  
In Chapter 3, we reviewed proposed therapeutics and vaccines for Ebola. Luckily, a modest 
neutralizing antibody response is enough to induce protection against the Ebola virus [16]. The 
challenge, however, is the timely production of vaccines and therapeutics with success record in 
actual human trials. A plant-made pharmaceutical (PMP) therapeutics, ZMapp, developed by the 
Mapp Pharm. Inc. successfully cured the two American Ebola patients and trigerred a global 
attention to PMP. Plant-made pharmaceuticals are particularly beneficial for timely production of 
recombinant pharmaceutical proteins in large scales, attracting a substantial attention from the 
pharmaceutical industry [20]. 
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Finally, despite the proven success of the mitigation efforts and therapeutics and vaccines 
in development, we are still far from total eradication of the disease. In this regard, it is of utmost 
importance that allocation of resources are not interrupted even if the public attention to Ebola 
news might weaken. Indeed, investments in proactive measures through health education and 
public awareness are a must after the “reactive phase” has successfully passed. The 2014 Ebola 
outbreak reminded us how much we are not prepared for a new infectious disease outbreak. In this 
regard, engagment of local communities in their own health, building reliable health 
infrastructures, and encouraging pharmaceutical companies to refocus their research in developing 
countries seem to be most effective in preparing the world to fight future infectious disease 
outbreaks. 
  
34 
References 
[1] http://www.cdc.gov/; accessed Oct 10, 2015 
[2] http://www.healthmap.org/ebola/#timeline , accessed Oct 10, 2015. 
[3] Food and Agriculture Organization of the United Nations, accessed Oct 10, 2015 
http://www.fao.org/emergencies/crisis/ebola/en/ 
[4] Althaus, C. L. (2014). Estimating the reproduction number of Ebola virus (EBOV) during the 
2014 outbreak in West Africa. PLoS currents, 6. 
[5] Huo, Xi, Ousmane Seydi, and Sénégal Thies. (2014).A Model of the 2014 Ebola Epidemic in 
West Africa with Contact Tracing. arXiv preprint arXiv:1410.3817  
[6] Chowell, G.,  Nishiura, H. (2014). Transmission dynamics and control of Ebola virus disease 
(EVD): a review. BMC medicine, 12(1), 196. 
[7] Nishiura, H.,  Chowell, G. (2015). Theoretical perspectives on the infectiousness of Ebola virus 
disease. Theoretical Biology and Medical Modelling, 12(1), 1. 
[8] Chowell, G.,  Viboud, C. (2015). Controlling Ebola: key role of Ebola treatment centres. The 
Lancet Infectious Diseases, 15(2), 139-141. 
[9] Althaus, C. L., Low, N., Musa, E. O., Shuaib, F.,  Gsteiger, S. (2015). Ebola virus disease 
outbreak in Nigeria: transmission dynamics and rapid control. Epidemics, 11, 80-84. 
[10] Akhtar, A., Befkadu, E., Basu, P.,  Kumar, P. (2014). Exposing the Origins of the Ebola 
Outbreak: Urging for a Shift in Response from Reactive to Proactive. American Journal of 
Infectious Diseases and Microbiology, 2(6A), 1-18. 
[11] Mcmahon, B. H., Fenimore, P. W., Del Valle, S. Y., Hengartner, N. W., Ribeiro, R. M.,  
Hyman, J. M. (2014). Modeling the impact of spatial heterogeneity, behavior change, and 
mitigations on the current Ebola epidemic (No. LA-UR-14-27813). Los Alamos National 
Laboratory (LANL). 
35 
[12] Dietz, K., Heesterbeek, J. A. P. (2002). Daniel Bernoulli’s epidemiological model revisited. 
Mathematical Biosciences, 180(1), 1-21. 
[13] Keeling, M. J., & Rohani, P. (2008). Modeling infectious diseases in humans and animals. 
Princeton University Press. 
[14] Klenk, H. D., & Becker, S. (2015). Ebola virus vaccines—preparing for the unexpected. 
Science, 349(6249), 693-694. 
[15] Marzi A, Halfmann P, Hill-Batorski L, Feldmann F, Shupert WL, Neumann G, Feldmann H, 
Kawaoka Y. (2015). An Ebola whole-virus vaccine is protective in nonhuman primates. Science, 
aaa4919. 
 [16] Cohen, J. (2014). Ebola vaccine: Little and late. Science, 345(6203), 1441-1442. 
[17] Choi, W. Y., Hong, K. J., Hong, J. E., Lee, W. J. (2015). Progress of vaccine and drug 
development for Ebola preparedness. Clinical and Experimental Vaccine Research, 4(1), 11-16. 
[18] Arntzen, C. (2015). Plant-­‐‑made pharmaceuticals: from ‘Edible Vaccines’ to Ebola 
therapeutics. Plant Biotechnology Journal, 13(8), 1013-1016. 
[19] Regules JA, Beigel JH, Paolino KM, Voell J, Castellano AR, Muñoz P, Moon JE, Ruck RC, 
Bennett JW, Twomey PS, Gutiérrez RL. (2015). A recombinant vesicular stomatitis virus Ebola 
vaccine—preliminary report. New England Journal of Medicine. published online 
April 1. DOI:10.1056/NEJMoa1414216. 
 [20] Sack, M., Hofbauer, A., Fischer, R., Stoger, E. (2015). The increasing value of plant-made 
proteins. Current Opinion in Biotechnology, 32, 163-170. 
[21] Zhang, Y., Li, D., Jin, X., Huang, Z. (2014). Fighting Ebola with ZMapp: spotlight on plant-
made antibody. Science China Life Sciences, 57(10), 987-988. 
36 
[22] Martin, J.E., Sullivan, N.J., Enama, M.E., Gordon, I.J., Roederer, M., Koup, R.A., Bailer, 
R.T., Chakrabarti, B.K., Bailey, M.A., Gomez, P.L. and Andrews, C.A., (2006). A DNA vaccine 
for Ebola virus is safe and immunogenic in a phase I clinical trial. Clinical and Vaccine 
Immunology, 13(11), 1267-1277.  
 
